Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Clinical trial NCT05296746 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05296746
Sponsor: SOLTI Breast Cancer Research Group
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Stage II

Start date: 2022-05-03
Primary completion: 2029-10-01
Enrollment: 1100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.